The reactivity of D antigen-specific monoclonal antibodies with infectious virus and inactivated virus in commercial poliovaccines from two manufacturers was examined in capture enzyme immunoassays. Epitopes on inactivated poliovirus types 2 and 3 in vaccines were modified by the inactivation process to such an extent that some monoclonal antibodies which bound to the homologous infectious virus strain failed to bind to the inactivated virus in the vaccine. This was especially the case for antibodies specific for site 1, which elicits the major immune response to these serotypes in mice.
Introduction
Inactivated poliovirus vaccines (IPV) are highly efficacious in protecting individuals against poliomyelitis. Poliovaccines are a trivalent blend of type 1, 2 and 3 strains, most often Mahoney, MEF and Saukett respectively, and high potency vaccines containing purified and concentrated virus are now being produced by several manufacturers. Two distinct antigenic forms of poliovirus exist, designated D and C antigen (Mayer et al., 1957) , sometimes referred to as N and H antigen. D antigen is expressed on native infectious virus and C antigen on non-infectious empty particles. Native D antigen can be converted into non-infectious C antigen by heating at 56 °C (Le Bouvier, 1955) . Convalescent sera react mainly with D antigen and sera from the acute phase of disease mainly with C antigen (Mayer et al., 1957) . As recovery from disease is associated with the development of antibodies against D antigen, it was believed that D antigen was the protective immunogen, and thus that only the D antigen content was important for the effectiveness of IPV. A gel diffusion method (van Ramshorst & Polak, 1966) and enzyme immunoassays (Souvras et al., 1980; van der Marel et al., 1980; Singer et al., 1989) have been developed for measuring D antigen content and the potency of vaccines is conventionally expressed in terms of arbitrarily defined D antigen units (Beale & Ungar, 1962) . High antigen content vaccines in general use, including those studied in this paper, take the form of highly purified prep-arations of D antigen with lrfinimal contamination by C antigen.
The antigenic structure of the three poliovirus serotypes has been studied extensively and the four main antigenic sites identified have been designated sites 1, 2, 3 and 4 (Minor, 1990) . Monoclonal antibodies which react with D (or N), C (or H) or both D and C (N and H) particles have been identified (Singer et al., 1989; Ferguson et al., 1984; Brioen et al., 1982) . For type 3 virus it has been shown that amino acid sequences at antigenic sites on infectious virus are also exposed on the surface of non-infectious C antigen but in a different conformation (Ferguson & Minor, 1990) .
Poliovirus for use in inactivated vaccine is treated with formalin at a temperature of 37 °C for a period of 10 to 14 days. It has been shown that the original Salk inactivated poliovaccines but not purified high potency preparations contained some C antigen (Singer et al., 1989) . Although Uhlig et al. (1983) reported that treatment of type 1 poliovirus with 3"7 % formaldehyde for 20 min at room temperature affected the binding of monoclonal antibodies to virus, no information is available on whether the inactivation process used in vaccine production results in chemical modification of antigenic sites and thus changes in the antigenicity of individual epitopes involved in the neutralization of poliovirus. Chemical modification could affect immunogenicity, but could also affect the antigenic properties used in measuring vaccine potency. This paper describes studies in which the reactivity in enzyme immunoassays of 0001-1341 © 1993 SGM panels of D antigen-specific monoclonal antibodies with infectious virus and inactivated vaccine was investigated.
Methods
Vaccines. The vaccines used in the study were from two different manufacturers. Vaccine A was supplied as a trivalent vaccine containing 40, 8 and 32 D antigen units for types 1, 2 and 3, respectively. Vaccine B was supplied as concentrated monovalent bulks containing 374, 792 and 132 D antigen units of type 1, 2 and 3 virus, respectively.
Infectious virus. The Mahoney, MEF and Saukett G and Saukett D strains (Minor et al., 1982) of type 1, 2 and 3 poliovirus respectively were grown on Hep2c cells and purified on sucrose gradients as described previously (Minor et al., 1980) . Virus strains designated Saukett G and Saukett D were obtained from the manufacturers of vaccines A and B, respectively.
Monoclonal antibodies. Monoclonal antibodies were prepared by fusion of splenocytes from immunized BALB/c mice and myeloma cells as previously described (Ferguson et at., 1984) . Ascites were prepared in syngeneic mice.
Enzyme immunoassays. Purified sheep anti-type 1 or anti-type 2 virus or rabbit anti-type 3 virus sera in carbonate/bicarbonate buffer pH 9.6 were added to 96-well microtitre plates (Greiner Labortecknic) and left overnight at 4 °C. Plates were washed four times with PBS containing 0"5 % Tween 20. As high background values were observed in assays of type 3 antigen, 2 % milk protein was added to this buffer for type 3 antigen assays. A series of four twofold dilutions of infectious virus or vaccine was added to each plate and incubated at 37 °C for 2 h. The antigen was then removed and the plates were washed as above. Monoclonal antibody (ascitic fluid diluted 1 : 100) was then added and the plates were reincubated at 37 °C for 1 h. After washing as above, peroxidase-conjugated goat anti-mouse serum (Sigma) was added and the plates were incubated at 37 °C for 1 h. Plates were then washed in PBS and o-phenylenediamine dihydrochloride in citrate/phosphate buffer was added. The reaction was stopped by addition of 1 ~-H~SO 4 and the absorbance was read at 492 nm. Assay data were evaluated by a parallel line analysis of log dose versus log absorbance (Finney, 1978) and the antigen content of vaccine was expressed relative to infectious virus which was arbitrarily assigned an antigen concentration of 1.0.
In order to facilitate the analysis of data, preliminary assays were carried out to determine pre-dilutions of virus and vaccines that gave comparable absorbance values. Three replicate assays for each virus type were then performed using the same series of dilutions.
Results

Specificity of EL1SAs
The specificities of the assays used in the study were examined by capturing monovalent type 1, 2 and 3 vaccines on to ELISA plates using type 1, 2 and 3 polyclonal sera. A mixture of the same type 1, 2 and 3 vaccines diluted to the same nominal concentration was also assayed on these plates to determine whether antigen of a single type was captured from the mixture as effectively as from monovalent antigen or whether there was interference, for example due to the specificity of the capture antibody. Monoclonal antibodies 237, 1050 and 1281, specific for types 1, 2 and 3 D antigen, respectively, were used to detect whether antigen had been captured. The results are shown in Table 1 . The antigen contents of the monovalent or the trivalent preparations were the same, indicating that the capture antisera are typespecific and that there is no interference in the detection of antigen of one type by the presence of antigen of the other two types.
Assays of type 1 component
Eight monoclonal antibodies directed against sites 2 and 4 of type 1 virus were assayed in enzyme immunoassays with infectious Mahoney virus, a monovalent vaccine (vaccine B) and a commercial vaccine containing all Table 2 (a) as the mean of three assays, including 95 % confidence limits. Vaccine A had an antigen content relative to infectious virus of approximately 0"8 when assayed with six of the antibodies (237, 431,428, 432, 429 and 234) and vaccine B an antigen content of approximately 1.0. However, the antigen contents determined with antibody 426 were apparently slightly higher being 0.9 for vaccine A and 1.4 for vaccine B. Conversely antibody 1585 gave apparently lower values of 0"70 and 0.72 respectively. The differences observed although suggestive were not statistically significant and further studies are required to establish whether they are real.
It was possible that individual antibodies might react to a greater extent with one vaccine compared to the other. Using the original assay data, the potency of vaccine A was thus expressed in terms of vaccine B rather than in terms of the live virus. The mean of the ratio obtained in three assays was calculated and the results along with 95 % confidence limits are given in Table 2 (b). The ratios ranged from 0.66, determined with antibody 426, to 0.98, determined with antibody 1585. This implies that the epitopes recognized by either 426 or 1585 or both were modified by inactivation with formalin to different degrees in vaccines A and B, although both were prepared with the same strain of virus and the formalin inactivation procedure described by Salk.
Assays of type 2 component
A panel of 12 type 2 monoclonal antibodies directed against various antigenic sites (Minor, 1990; Patel et al., 1993) was examined, and the results are presented in Table 3 (a). Four antibodies (269, 436, 437 and 1232) bound to infectious virus, but failed to react with the same strain of virus in inactivated form in either vaccine A or B. Antibodies 269, 436 and 437 are directed against site 1 but the site of reactivity of 1232 has not yet been identified. The antigen contents of each preparation were determined with the remaining eight monoclonal antibodies and are shown in Table 3 (a). The antigen content of vaccine A was between 0-34 and 0.64 and that of vaccine B was between 0.7 and 1.22 when infectious MEF virus was assigned an antigenic content of 1'0. The confidence intervals suggested that antigen contents determined with antibody 434 were significantly higher than those determined with 1231 for both vaccines A and B. This suggested that the epitopes to which they bind might have been modified either to reduce binding of 1231, or to increase binding of 434, or both. When the ratio of the antigen content of vaccine A to that of type 2 vaccine B was calculated as shown in Table 3 (b), it appeared that, compared to the reactivities of the other antibodies, antibody 1269 reacted better with vaccine A than vaccine B, suggesting that the epitope which it recognized may be modified to a different extent in the two vaccines.
Assays of type 3 component
Studies with monoclonal antibodies and T1 RNase oligonucleotide maps carried out on 'Saukett' viruses obtained from different laboratories and manufacturers revealed considerable antigenic and genetic differences between strains (Minor et al., 1982) . Subsequent sequencing studies revealed nucleotide variation at regions coding for antigenic sites (Kinnunen & Hovi, 1989) . Vaccine A was derived from Saukett G which was readily distinguished from Saukett D (Minor et al., 1982) , the virus strain used in the production of vaccine B. Both strains were therefore included in this study and the antigen contents of vaccines A and B calculated in terms of a preparation of infectious virus of the homologous strains Saukett G and D, respectively. In preliminary studies, antibodies 165 and 199 failed to react with either vaccine A or infectious Saukett G virus from which it was prepared, but reacted with infectious Saukett D virus. However, these antibodies did not react with vaccine B indicating that the site on Saukett D virus had been modified during the inactivation process. The remaining 17 monoclonal antibodies shown in Table 4 reacted with both Saukett G and Saukett D, but several antibodies reacted differently with viruses after inactivation. For vaccine A, an antigen content of between 0.8 and 1-11 was obtained with D antigen-specific antibodies 208, 520 and 1281. This value, assessed with antibodies against different sites, may represent the amount of unmodified antigen present. Several other antibodies gave slightly lower potencies which in view of the errors in the estimations were not statistically significant. Antibody 441 gave an antigen content of 0.70, antibody 442 of 0-57, antibody 134 of 0.64 and antibody 877 of 0.63. Two other antibodies gave lower values of 0.36 (antibody 132) and 0-02 (antibody 439), but seven antibodies failed to react with the vaccine at all. These included five directed against site 1, namely antibodies 214, 440, 471, 113 and 194 , and two against site 2b, namely antibodies 875 and 880.
The antigen content of vaccine B gave a similar range of values although different antibodies were involved. The highest antigen contents were determined with antibodies 208, 520 and 877, and antibodies 134, 132 and 1281 gave intermediate values. Antibodies 194, 439, 441 and 442 reacted very poorly and antibody 113 even more weakly. Antibodies 214, 440, 471, 875 and 880 failed to react at all.
Differences in the reactivity of the antibodies with the two vaccines were seen, particularly with antibodies 441 and 442 which were in the intermediate or highly reactive group for vaccine A, but in the poorly reactive group for vaccine B. Similar but less extreme differences were seen with antibodies 877 and 132.
The antigen contents of vaccines A and B were measured using antibody 495, which was directed against site 1 but which reacted with both D and C antigens. Values of 1.09 and 1.12 were obtained for vaccines A and B, respectively. These values were comparable to the highest antigen contents obtained for the type 3 vaccine.
Discussion
The studies described here indicate that the formalin inactivation process used in the production of high potency IPV modifies some epitopes on poliovirus to such an extent that they are no longer recognized by monoclonal antibodies. Sites 1 of types 2 and 3 were the most extensively modified according to their reaction with the monoclonal antibodies described here. This may be partially due to their prominence on the virus, as the main component of the site is a highly exposed loop at the pentameric axis of the virus particle. The sequence of the loop also contains basic residues including the arginine and lysine residues that are the target of trypsin and trypsin-like enzymes and also presumably of formaldehyde. The other site known to be modified was site 2b of VP2 of type 3, also a continuous and exposed sequence. It is of interest that a number of other monoclonal antibodies that react with sites 1 and 2b in both D and C antigen-expressing particles continued to react with inactivated virus, whereas the affected antibodies were all D antigen-specific (data not shown). We have previously reported that D + C-reactive antibodies react well with antigenic chimeras in which sites have been exchanged between type 1 and type 3 but D-specific antibodies do not . Thus the binding of D+C-reactive antibodies appears to be generally less easily disrupted than that of D antigenspecific antibodies, as might be predicted.
In addition to the total loss of activity of certain epitopes there is a suggestion that other epitopes may have been affected so as to reduce or increase their reactivity. This was most obvious for type 3 but may also occur for type 2 and depended on the strain studied. The observation that different vaccines were possibly affected to different degrees even where the same virus strain was used suggests that there may be slight but significant differences in the manufacturing processes. Further studies are currently in progress to establish whether this is the case.
From the data presented here it would appear that the antigenic structure of virus types 2 and 3 is affected by the inactivation process to a greater extent than type 1. However this may be a reflection of the monoclonal antibodies used and the lack of availability of type 1 site 1 antibodies. For type I and 3 polioviruses, site 3 appears to be strain-specific (Minor et al., 1987) and, since most of the antibodies available were prepared from mice immunized with Sabin vaccine rather than Saukett virus strains, the effect of formalin on this site could not be evaluated. However site 3 may not be associated with the protective immune response to IPV as a broadly reactive rather than a strain-specific response would be required to protect against challenge by wild viruses.
Enzyme immunoassays involving polyclonal sera have been developed in several laboratories, and quantification of poliovirus antigens in IPV using monoclonal antibodies has also been reported (Singer et al., 1989) . Although the use of D antigen-specific monoclonal antibodies is useful in measuring the potency of IPV, the data given here also indicate that considerable care has to be taken in the selection of antibodies.
As the inactivated virus appears to be antigenically different from native virus, the spectrum of antibodies induced will be altered by inactivation and it is likely that some antibodies induced by the modified sites wilt react poorly with the native virus. We have previously reported a phenomenon of this kind with chimeric polioviruses in which antigenic sites of type 1 were replaced with the corresponding regions of type 3. The reactivity of the chimeras with polyclonal and monoclonal antibodies specific for type 3 reflected the sequence transferred and also the ability of the chimeras to induce antibodies reactive with native type 3 virus . Similar observations were reported for type 1 and type 2 virus (Murdin & Wimmer, 1989) .
Since the D antigen content of inactivated vaccines can be related to plaque-forming units for each virus strain, as shown by the studies described here, comparative immunogenicity studies are being performed to investigate the extent to which formalin inactivation has affected the viral immunogenicity as well as antigenicity.
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